Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Kancera Yönetim

Yönetim kriter kontrolleri 1/4

Kancera's CEO'su Peter Selin, Jul2023 tarihinde atandı, in görev süresi 1.25 yıldır. şirketin hisselerinin 0.026% doğrudan sahiptir ve bu hisselerin değeri SEK 62.15K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.6 yıl ve 12.8 yıldır.

Anahtar bilgiler

Peter Selin

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.3yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	12.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Peter Selin (51 yo)

1.3yrs

Görev süresi

Mr. Peter Selin serves as Chief Executive Officer of Kancera AB (publ) since July 1, 2023. He had been an Executive Vice president of Corporate Development & Finance at Kancera AB (publ) since May 01, 2022...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas Olin	Executive VP & Director	less than a year	SEK 3.57m	0.30% SEK 690.9k
Peter Selin	Chief Executive Officer	1.3yrs	Veri yok	0.026% SEK 59.6k
Hans Richter	Chief Financial Officer	no data	Veri yok	Veri yok
Robert Edfors	Chief Scientific Officer & Senior Vice President of Clinical Development	less than a year	Veri yok	Veri yok
Niclas Brynne	Head of Clinical Development	no data	Veri yok	0.024% SEK 55.2k
Markus Jerling	Chief Medical Officer	1.1yrs	Veri yok	Veri yok

0.6yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim: KAN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas Olin	Executive VP & Director	14.8yrs	SEK 3.57m	0.30% SEK 690.9k
Charlotte Edenius	Independent Director	8.3yrs	SEK 125.00k	0% SEK 0
Håkan Mellstedt	Independent Director	14.8yrs	SEK 125.00k	0.17% SEK 407.8k
Erik Nerpin	Independent Chairman of the Board	14.8yrs	SEK 175.00k	0.24% SEK 555.6k
Carl-Henrik Heldin	Independent Director	12.8yrs	SEK 125.00k	0.066% SEK 153.9k
Anders Gabrielsen	Independent Director	6.2yrs	SEK 125.00k	Veri yok
Petter Brodin	Independent Director	3.4yrs	SEK 75.00k	Veri yok

12.8yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: KAN 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 12.8 yıldır).

Kancera Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Insufficient new directors

Recent updates

Kancera AB (Publ) Provides Operational Update Concerning Its Clinical Development Program

New minor risk - Share price stability

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Kancera AB's Fractal Study Results to Be Presented at the ESC 2024 Conference

New major risk - Financial position

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ) Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects

New major risk - Shareholder dilution

Forecast breakeven date pushed back to 2025

Kancera AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 73.011989 million.

New major risk - Financial position

New major risk - Share price stability

Kancera AB (publ) Reports Positive Top Line Results from the FRACTAL Study

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Forecast breakeven date moved forward to 2024

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

New major risk - Share price stability

Kancera AB (Publ) Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Kancera AB (publ) Reports Dosing of First Patient in the KANDOVA Study

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Forecast to breakeven in 2025

Kancera AB (publ) Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer

Insufficient new directors

Kancera AB (publ) Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies

Kancera AB (publ) Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma

Kancera AB (publ) Reports Good Progress of Recruitment in Ongoing Phase IIa Study of Kand567 in Myocardial Infarction and the Decision to Allow for Recruitment of Additional Patients

Kancera AB (publ) Reports Convincing Preclinical Results and Decision to Initiate Clinical Development of KAND567 in Ovarian Cancer

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Insufficient new directors

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Insufficient new directors

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

First quarter 2021 earnings released: kr0.029 loss per share (vs kr0.56 loss in 1Q 2020)

Insider recently bought kr65k worth of stock

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Full year 2020 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2019)

New 90-day low: kr1.62

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

New 90-day low: kr2.23

New 90-day low: kr2.37

Kancera AB (publ) to Report Q3, 2021 Results on Nov 19, 2021

New 90-day high: kr3.98

First half earnings released

New 90-day high - kr2.96

Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş